IGF Oncology, LLC   Report issue

For profit Phase 2
Founded: St Louis MO United States (2004)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2014
NCT02045368
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

igf-methotrexate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Refractory (Phase 2)

Anemia, Refractory, with Excess of Blasts (Phase 2)

Brain Neoplasms (Phase 1)

Gastrointestinal Neoplasms (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Urogenital Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1